@article{55b2961c3d8b47dc864506493b08e010,
title = "Metabolomic characterization of a cf. Neolyngbya cyanobacterium from the south china sea reveals wenchangamide a, a lipopeptide with in vitro apoptotic potential in colon cancer cells",
abstract = "Metabolomics can be used to study complex mixtures of natural products, or secondary metabolites, for many different purposes. One productive application of metabolomics that has emerged in recent years is the guiding direction for isolating molecules with structural novelty through analysis of untargeted LC-MS/MS data. The metabolomics-driven investigation and bioassay-guided fractionation of a biomass assemblage from the South China Sea dominated by a marine filamentous cyanobacteria, cf. Neolyngbya sp., has led to the discovery of a natural product in this study, wenchangamide A (1). Wenchangamide A was found to concentration-dependently cause fast-onset apoptosis in HCT116 human colon cancer cells in vitro (24 h IC50 = 38 µM). Untargeted metabolomics, by way of MS/MS molecular networking, was used further to generate a structural proposal for a new natural product analogue of 1, here coined wenchangamide B, which was present in the organic extract and bioactive sub-fractions of the biomass examined. The wenchangamides are of interest for anticancer drug discovery, and the characterization of these molecules will facilitate the future discovery of related natural products and development of synthetic analogues.",
keywords = "Anticancer, Cyanobacteria, Drug discovery, Metabolomics, Natural products, Neolyngbya, Secondary metabolites, South China Sea, Wenchangamide",
author = "Lijian Ding and Rinat Bar-Shalom and Dikla Aharonovich and Naoaki Kurisawa and Gaurav Patial and Shuang Li and Shan He and Xiaojun Yan and Arihiro Iwasaki and Kiyotake Suenaga and Chengcong Zhu and Haixi Luo and Fuli Tian and Fuad Fares and Naman, {C. Benjamin} and Tal Luzzatto-Knaan",
note = "Funding Information: Funding: This study was supported by the National Key Research and Development Program of China, funded through MOST (the Ministry of Science and Technology of China; grant 2018YFC0310900 to X.Y., S.H. and C.B.N.), NSFC (The National Natural Science Foundation of China; grants 81850410553 and 82050410451 to C.B.N.), the National 111 Project of China (D16013), CSC (China Scholarship Council; no. 201908330173 to L.D.), and the Li Dak Sum Yip Yio Chin Kenneth Li Marine Biopharma-ceutical Development Fund of Ningbo University. Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",
year = "2021",
month = jul,
doi = "10.3390/md19070397",
language = "English",
volume = "19",
journal = "Marine Drugs",
issn = "1660-3397",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "7",
}